Hälsa & medicin
5.1
Study reveals which cervical cancer patients benefit most from added treatment
A new analysis of the SCCAN trial identifies which intermediate-risk cervical cancer patients should receive additional therapy after surgery, potentially sparing others from unnecessary treatment. The findings could reshape clinical guidelines and reduce healthcare costs while improving patient outcomes.
Originaltitel: Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study